Dyax’s HAE Candidate Meets Clinical Endpoints In Phase III Trial
With the completion of Phase III testing, Dyax plans to submit final piece of rolling BLA for DX-88 in early fourth quarter.
With the completion of Phase III testing, Dyax plans to submit final piece of rolling BLA for DX-88 in early fourth quarter.